Coya rises on data from Alzheimer's disease treatment trial

Coya Therapeutics

16/05/2023 17:29

** Drug developer Coya Therapeutics Inc's shares  COYA.O 
rise 12.1% to $5.94
    ** Co reports positive data from an open-label,
proof-of-concept study in 8 Alzheimer's disease (AD) patients
for its experimental treatment, COYA 301 
    ** Says COYA 301 enhanced the function of regulatory T cells
and halted cognitive decline, when tested on a scale used to
measure the severity of the disease
    ** Treatment appeared to be well tolerated in patients with
AD - Co
    ** Co adds over the study course the treatment also lowered
the levels of biomarkers and a type of pro-inflammatory proteins
in AD patients
    ** Including session's gain, co's stock up ~23% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))